Literature DB >> 1978614

Vecuronium neuromuscular blockade at the diaphragm, the orbicularis oculi, and adductor pollicis muscles.

F Donati1, C Meistelman, B Plaud.   

Abstract

To determine the relationship among diaphragm, orbicularis oculi, and adductor pollicis blockade, train-of-four stimulation was applied to the phrenic, facial, and ulnar nerves in 16 adult patients anesthetized with alfentanil-propofol-oxygen. Vecuronium 0.04 or 0.07 mg/kg was given. The response of the adductor pollicis was measured with a force transducer, and that of the other muscles by electromyography (EMG). No statistically significant differences were detected with either dose in the intensity of maximum blockade measured at the three muscles. With 0.04 mg/kg, the first response (T1) in the train-of-four was decreased (mean +/- SEM) 78 +/- 8, 62 +/- 11, and 84 +/- 3% for the diaphragm, orbicularis oculi, and adductor pollicis, respectively. Corresponding values after 0.07 mg/kg were 95 +/- 3, 82 +/- 11, and 95 +/- 2%, respectively. However, onset time was longer at the adductor pollicis than at the diaphragm, and the orbicularis oculi onset time approached that of the diaphragm. With 0.04 mg/kg, time to maximum diaphragmatic blockade was 2.9 +/- 0.3 min, compared with 3.7 +/- 0.6 min at the orbicularis oculi (no significant difference [NS]) and 6.6 +/- 0.4 min at the adductor pollicis (P less than 0.001). With vecuronium 0.07 mg/kg the values were 2.2 +/- 0.3, 3.4 +/- 0.5 (P = 0.024), and 6.3 +/- 0.6 (P less than 0.001), respectively. Time to 75% T1 recovery was similar at the diaphragm and the orbicularis oculi, but significantly longer at the adductor pollicis.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1978614     DOI: 10.1097/00000542-199011000-00013

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  12 in total

Review 1.  Muscle relaxant use during intraoperative neurophysiologic monitoring.

Authors:  Tod B Sloan
Journal:  J Clin Monit Comput       Date:  2012-09-27       Impact factor: 2.502

2.  Hydraulic analog for simultaneous representation of pharmacokinetics and pharmacodynamics: application to vecuronium.

Authors:  E Nikkelen; W L van Meurs; M A Ohrn
Journal:  J Clin Monit Comput       Date:  1998-07       Impact factor: 2.502

3.  Duration of succinylcholine and vecuronium blockade but not potency correlates with the ratio of endplate size to fibre size in seven muscles in the goat.

Authors:  C Ibebunjo; C B Srikant; F Donati
Journal:  Can J Anaesth       Date:  1996-05       Impact factor: 5.063

Review 4.  Pharmacokinetics and pharmacodynamics of rapacuronium bromide.

Authors:  William J Wight; Peter M C Wright
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

5.  Effects of sepsis on the neuromuscular blocking actions of d-tubocurarine on rat adductor and abductor laryngeal muscles.

Authors:  Kohki Nishikawa; Eichi Narimatsu; Motohiko Igarashi; Akiyoshi Namiki
Journal:  J Anesth       Date:  2009-11-18       Impact factor: 2.078

6.  Rapid tracheal intubation with atracurium: the timing principle.

Authors:  K F Koh; F G Chen
Journal:  Can J Anaesth       Date:  1994-08       Impact factor: 5.063

7.  Surgeon-controlled mivacurium administration during elective caesarean section.

Authors:  M Abdulatif; E Taylouni
Journal:  Can J Anaesth       Date:  1995-02       Impact factor: 5.063

8.  Succinylcholine and vecuronium blockade of the diaphragm, laryngeal and limb muscles in the anaesthetized goat.

Authors:  C Ibebunjo; L W Hall
Journal:  Can J Anaesth       Date:  1994-01       Impact factor: 5.063

Review 9.  Monitoring of neuromuscular function in the clinical setting.

Authors:  D Kelly; S J Brull
Journal:  Yale J Biol Med       Date:  1993 Sep-Oct

10.  Recovery of post-tetanic and train-of-four responses at the first dorsal interosseous and adductor pollicis muscles in patients receiving vecuronium.

Authors:  Y Saitoh; H Tanaka; H Toyooka; K Amaha
Journal:  Can J Anaesth       Date:  1996-04       Impact factor: 6.713

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.